Printer Friendly

Rabobank disappointed with Arseus' organic growth, recommends "hold".

M2 PHARMA-July 8, 2011-Rabobank disappointed with Arseus' organic growth, recommends "hold"(C)2011 M2 COMMUNICATIONS

8 July 2011 - Rabobank cheered the second-quarter revenues of Belgian health products wholesaler Arseus (EBR: RCUS), but said it is disappointed with its organic growth.

The bank maintained its "hold" recommendation and EUR12.50 share price target.

Arseus' second-quarter revenues grew by 12.5% on the year to EUR121.4m (USD174.2m), slightly up from the projected EUR120.4m by Rabobank. Organically, revenues grew by 2.7%, while the bank had bet on a 3.5% rise.

The Fagron division achieved the highest organic growth of 6.7%. All other divisions showed a disappointing organic development, according to the bank.

For full 2011, Arseus expects organic revenue growth of 3% to 6%. According to Rabo, the revenue growth is currently at the lower end of the range.

At 08:27 GMT on Friday Arseus shares gained 2.41% to EUR11.49 in Brussels trading.

(EUR1 = USD1.435)

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 8, 2011
Words:173
Previous Article:Innate Pharma shares rise 49% on Thursday.
Next Article:InVivo Therapeutics submits IDE application to FDA for biopolymer scaffolding device.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters